FindTrial
Sign In

TA-650

DRUG6 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Behcet SyndromeBehcet's DiseaseCrohn's DiseaseKawasaki Disease Refractory to Initial Therapy With Intravenous ImmunoglobulinNeuro-Behcet's DiseasePediatric Crohn's DiseasePediatric Ulcerative ColitisPlaque Psoriasis

Phase 3

Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
CompletedNCT00805766
Tanabe Pharma CorporationCrohn's Disease
Start: 2008-12-31End: 2010-07-31Updated: 2026-01-07
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
CompletedNCT01532570
Tanabe Pharma CorporationBehcet's Disease, Behcet Syndrome, Neuro-Behcet's Disease
Start: 2012-01-31End: 2014-05-31Updated: 2026-01-07
Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
CompletedNCT01580670
Tanabe Pharma CorporationPediatric Crohn's Disease
Start: 2012-03-31End: 2015-03-31Updated: 2026-01-07
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
CompletedNCT01585155
Tanabe Pharma CorporationPediatric Ulcerative Colitis
Start: 2012-02-29End: 2014-09-30Updated: 2026-01-07
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
CompletedNCT01596335
Tanabe Pharma CorporationKawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Start: 2012-05-31End: 2014-10-31Updated: 2026-01-07
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
CompletedNCT01680159
Tanabe Pharma CorporationPlaque Psoriasis, Psoriatic Arthritis, Psoriatic Erythroderma +1
Start: 2012-07-31End: 2015-03-31Updated: 2026-01-08

Related Papers

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
2019-10-134 citations
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
Scientific Reports2018-01-2576 citations